The EMEA suspends approval of Raptiva for psoriasis : Commentary;EMEA setzt die Zulassung von Raptiva für die Therapie der Psoriasis aus : Kommentar

Hautarzt

Volumn 60, Issue 4, 2009, Pages 345-346

  Prinz, J C ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; EFALIZUMAB; ETANERCEPT; INFLIXIMAB; NATALIZUMAB;

HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MEDICAL SOCIETY; MENINGITIS; NOTE; OPPORTUNISTIC INFECTION; PSORIASIS; REMISSION; SEPSIS; TREATMENT INDICATION;

ANTIBODIES, MONOCLONAL; DRUG APPROVAL; EUROPEAN UNION; HUMANS; PRODUCT SURVEILLANCE, POSTMARKETING; PSORIASIS;

EID: 65049087163     PISSN: 00178470     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00105-009-1743-z     Document Type: Note

References (1)

1. PRESS RELEASE (2009) European Medicines Agency recommends suspension of the marketing authorisation of Raptiva (efalizumab). London, Doc. Ref. EMEA/CHMP/20857/2009